Massachusetts, US-based consumer products designer and manufacturer Philips North America has agreed to acquire the medical device sales and service business unit contracts of Georgia, US-based health care solutions provider Digirad
's Cardius X-ACT(TM), a dedicated cardiac SPECT system, is expected to set a new clinical standard with X-ACT attenuation correction.
"These important revenue milestones build on Digirad
's prior successful funding event," commented John Dahldorf, Co-CEO and CFO, Digirad
Using advanced manufacturing techniques, Digirad
has fabricated large-area monolithic arrays of SpectrumPlus CZT detectors for imaging a variety of radioactive materials.
Corporation, a pioneer in the field of solid-state nuclear detector technology for the healthcare industry, signed the 5,000 s/f lease at 475 Mola Boulevard to enable the company to better service their clients throughout northern New Jersey.
announced that its Board of Directors has approved the conversion of Digirad
into a diversified holding company, and the acquisition of ATRM Holdings as an initial "kick-off" transaction.
Some of the major players in the global Nuclear Medicine Equipment Market include Philips Healthcare (Netherlands), GE Healthcare, Siemens Healthcare (Germany), Digirad
Corp., Mediso Medical Imaging Systems, Ltd.
Companies Mentioned in this Report: DDD-Diagnostic, Digirad
, GE Healthcare, GVI Medical Devices, Mediso Medical Imaging Systems, NeuroLogica, Neusoft Medical Systems, NuCare Medical Systems, Oncovision, Philips Healthcare, Shimadzu, Siemens Healthcare, SurgicEye, Toshiba Medical
SCOTT HUENNEKENS, CEO of DIGIRAD
CORPORATION, describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.
Aviragen shareholders Digirad
Corporation, East Hill Management Company and Thomas M.
Diagnostic solution company Digirad
Corporation (NasdaqGM:DRAD) disclosed on Friday that its adjusted net income was USD1.3m (USD0.07 per diluted share) for the first quarter ended 31 March 2016.